EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, JW (Cayman) Therapeutics Co's Enterprise Value is $49.60 Mil.
JW (Cayman) Therapeutics Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-10.99 Mil. Therefore, JW (Cayman) Therapeutics Co's EV-to-FCF for today is -4.51.
The historical rank and industry rank for JW (Cayman) Therapeutics Co's EV-to-FCF or its related term are showing as below:
JWCTF'
s EV-to-FCF Range Over the Past 10 Years
Min: -10.94 Med: -0.58 Max: 1.09
Current: -4.03
During the past 8 years, the highest EV-to-FCF of JW (Cayman) Therapeutics Co was 1.09. The lowest was -10.94. And the median was -0.58.
JWCTF's EV-to-FCF is ranked worse than 100% of 331
companies
in the Biotechnology industry
Industry Median: 15.9
vs JWCTF: -4.03
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
JW (Cayman) Therapeutics Co (OTCPK:JWCTF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
JW (Cayman) Therapeutics Co's PE Ratio (TTM) for today is calculated as:
JW (Cayman) Therapeutics Co's share price for today is $0.2375.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. JW (Cayman) Therapeutics Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.188.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
JW (Cayman) Therapeutics Co EV-to-FCF Related Terms
JW (Cayman) Therapeutics Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JW (Cayman) Therapeutics Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where JW (Cayman) Therapeutics Co's EV-to-FCF falls into.
JW (Cayman) Therapeutics Co's current Enterprise Value is $49.60 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. JW (Cayman) Therapeutics Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-10.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JW (Cayman) Therapeutics Co (JWCTF) has a EV-to-FCF of -4.51 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on JW (Cayman) Therapeutics Co and its competitors. According to the industry distribution chart, JW (Cayman) Therapeutics Co ranks #999999 out of 331 companies in the Biotechnology industry.
Is JW (Cayman) Therapeutics Co's EV-to-FCF too high?
JW (Cayman) Therapeutics Co's current EV-to-FCF is -4.51. Based on the distribution chart, JW (Cayman) Therapeutics Co ranks #999999 out of 331 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, JW (Cayman) Therapeutics Co has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JW (Cayman) Therapeutics Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, JW (Cayman) Therapeutics Co ranks #999999 out of 331 companies for EV-to-FCF. This places JW (Cayman) Therapeutics Co in the lower half of its industry. The industry median EV-to-FCF is 15.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.90, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on JW (Cayman) Therapeutics Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JW (Cayman) Therapeutics Co's current EV-to-FCF is -4.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JW (Cayman) Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co (JWCTF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.24 — trading 58.3% below its estimated fair value. The current EV-to-FCF is -4.51. JW (Cayman) Therapeutics Co's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For JW (Cayman) Therapeutics Co (JWCTF), the current EV-to-FCF is -4.51 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JW (Cayman) Therapeutics Co (JWCTF) Overvalued in 2026?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued.
The current stock price of $0.24 is trading 58.3% below its estimated GF Value™ of $0.57.
GuruFocus considers JW (Cayman) Therapeutics Co to be Possible Value Trap.
Key valuation signals for JWCTF:
EV-to-FCF: -4.51
GF Value™: $0.57 vs. price of $0.24 (58.3% below fair value)
No single metric tells the full story. See the JWCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
28GF Score
Get the complete analysis for JWCTF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JWCTF has been successfully added to your 
